Furthermore, as recently highlighted in a study by Keating and Wild [35], the increased interest in GLP-1 medications among women was likely fueled by the lack of appropriate and effective care for women, especially those diagnosed with PCOS—the most prevalent endocrinopathy among women of reproductive age, impacting 6% to 20% of women [22,36]. The gene discussed is GLP1R; the disease is endocrine system disorder.